FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Emerging growth company ☐ TABLE OF CONTENTS | --- | --- | |----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - The net loss for the first quarter of 2023 was $7.9 million, a slight improvement from a net loss of $8.3 million in the same period in 2022 [48] - Cash, cash equivalents, and marketable securities totaled $34.5 million as of March 31, 2023, down from $42.3 million at the end of 2022 [49] - Research and development expenses decreased to $4.6 million in Q1 2023 from $5.1 million in Q1 2022, reflecting a focus on managing cash burn [3][4] Business Line Data and Key Metrics Changes - The ongoing Phase 1/1b trial of CPI-818 in T cell lymphoma has shown promising results, with two complete responses and three partial responses among 19 evaluable patients [15][19] - The median progression-free survival (PFS) for patients with an absolute lymphocyte count (ALC) above 900 was reported at 19.9 months, compared to just 2.1 months for those below 900 [69] Market Data and Key Metrics Changes - The company is preparing for a meeting with the FDA in Q3 2023 to discuss a Phase 3 clinical trial for CPI-818, which is expected to include approximately 150 patients [5][14] - The company is also focused on expanding the application of CPI-818 beyond T cell lymphoma to solid tumors, supported by recent preclinical data [7][10] Company Strategy and Development Direction - The company is prioritizing CPI-818 as its most advanced ITK inhibitor, aiming for a potential registration trial for T cell lymphoma [10][50] - There is an emphasis on establishing collaborations to support the development of product candidates and managing cash burn effectively [4][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential of CPI-818 to address unmet needs in cancer treatment [10][19] - The company plans to present additional interim data at the International Conference on Malignant Lymphoma in June 2023, which may further validate the efficacy of CPI-818 [51][60] Other Important Information - The company has extended its intellectual property covering CPI-818, with patents issued in multiple countries [17] - The safety profile of CPI-818 appears favorable, with no dose-limiting toxicities observed in trials [53] Q&A Session Summary Question: What is the expected design for the Phase 3 trial with the FDA? - Management expects to discuss the trial design and standard therapies in the control arm, with a focus on a randomized controlled trial [74][75] Question: What are the historical response rates for the control agents? - The overall response rate (ORR) for standard agents is about 25%, with short-lived responses [76] Question: Will there be an interim look at the data for response rates? - Management confirmed plans for an interim look at the data, consistent with recent FDA guidelines [43] Question: What is the plan for CPI-818 in immune diseases? - The company is still considering whether to move into immune diseases with CPI-818, depending on progress in cancer indications [91] Question: Is there any delay in the ciforadenant trial? - Management clarified that there is no slowdown in the ciforadenant trial, which is actively enrolling patients [92]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commissio ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Mara Goldstein - Mizuho Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commission Fil ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Jerry Gong - Mizuho Securities Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmace ...

Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Comm ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer James Rosenbaum - Senior President of Research Conference Call Participants Sean Lee - H.C. Wainwright Operator Good afternoon, and welcome to the Corvus Pharmaceutical Second Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation ...

Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commissio ...

Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commissi ...